Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NAPROSYN vs INDOCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Juvenile arthritis,Tendonitis,Bursitis,Acute gout,Primary dysmenorrhea,Mild to moderate pain
Moderate to severe rheumatoid arthritis,Ankylosing spondylitis,Osteoarthritis,Acute gouty arthritis,Acute painful shoulder (bursitis/tendinitis),Patent ductus arteriosus in neonates (off-label)
250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.
25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.
Terminal elimination half-life is 12-17 hours. This long half-life allows twice-daily dosing, but may lead to drug accumulation in elderly or renally impaired patients.
Terminal elimination half-life approximately 4.5 hours (range 2.6–11.2 hours); prolonged in elderly and patients with hepatic impairment.
Extensively metabolized in the liver via glucuronidation and oxidation; CYP450 involvement is minor. Major metabolite is 6-desmethylnaproxen.
GFR 30-59 m L/min: decrease dose by 50% or use alternative; GFR <30 m L/min: contraindicated.
Cr Cl 10-50 m L/min: dose reduction 50%; Cr Cl <10 m L/min: avoid use or reduce to 25% of usual dose.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. Increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation, which can be fatal.
First trimester: Case-control studies suggest a small increased risk of cardiac defects and oral clefts; absolute risk remains low. Second/third trimester: Exposure may cause premature constriction of the ductus arteriosus, oligohydramnios due to fetal renal effects, and risk of necrotizing enterocolitis, intracranial hemorrhage, and renal dysfunction in the neonate; avoid after 30 weeks gestation.
First trimester: Avoid because of risk of spontaneous abortion and congenital malformations (cardiac, orofacial clefts) based on epidemiologic studies. Second/third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment.
Naprosyn (naproxen) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~12-17 hours), allowing twice-daily dosing. Use with caution in patients with cardiovascular disease, renal impairment, or history of GI bleeding. It can mask signs of infection. Monitor renal function and blood pressure regularly. Avoid concurrent use with other NSAIDs or anticoagulants due to increased bleeding risk. Naprosyn may cause photosensitivity; advise sun protection.
Indomethacin (Indocin) is a potent NSAID with significant anti-inflammatory, analgesic, and antipyretic effects. It is particularly effective for acute gout flares and closure of patent ductus arteriosus (PDA) in neonates. Due to high risk of gastrointestinal bleeding, renal impairment, and cardiovascular events, use the lowest effective dose for the shortest duration. Contraindicated in patients with history of aspirin or NSAID-induced asthma, urticaria, or allergic reactions. Monitor renal function, blood pressure, and signs of GI bleeding. Avoid concurrent use with other NSAIDs, anticoagulants, and corticosteroids.
No interactions on record
No interactions on record
Common clinical questions about NAPROSYN vs INDOCIN, answered by our medical review team.
NAPROSYN is a NSAID that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This results in decreased inflammation, pain, and fever.. INDOCIN is a NSAID that works by Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever. It also decreases renal blood flow and may cause ductus arteriosus closure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NAPROSYN and INDOCIN depend on the specific clinical indication. These are both NSAID agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NAPROSYN is: 250-500 mg orally twice daily; maximum 1500 mg/day. For extended-release: 750-1000 mg orally once daily.. The standard adult dose of INDOCIN is: 25 mg orally 2-3 times daily; maximum 200 mg/day. Intravenous: 0.5-1 mg/kg as single dose for ductus arteriosus closure.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NAPROSYN and INDOCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NAPROSYN is classified as Category C. First trimester: Case-control studies suggest a small increased risk of cardiac defects and oral clefts; absolute risk remains low. Second/third trimester: Exposure may cause prema. INDOCIN is classified as Category C. First trimester: Avoid because of risk of spontaneous abortion and congenital malformations (cardiac, orofacial clefts) based on epidemiologic studies. Second/third trimester: Cont. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Primarily hepatic metabolism via O-demethylation and N-deacylation; minor pathways include glucuronidation. Involved enzymes include CYP2C9 and possibly CYP3A4.
Renal excretion of conjugated metabolites accounts for approximately 95% of a dose, with 1-2% as unchanged naproxen. Fecal excretion is minimal (<5%).
Renal (60% as unchanged drug and glucuronide conjugates), biliary/fecal (33% via enterohepatic circulation).
>99% bound to albumin.
Approximately 90% bound to albumin (saturable binding at high concentrations).
0.16 L/kg (approximately 10-12 L in a 70 kg adult). Low Vd indicates distribution primarily in plasma and extracellular fluid.
0.1–0.2 L/kg (indicating low tissue penetration; primarily in plasma and interstitial fluid).
Oral: 95% (completely absorbed). Rectal: approximately 80% of oral bioavailability.
Oral: 100% (immediate release); Rectal: 80–90%; IV: 100%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
For juvenile arthritis: 10-15 mg/kg/day divided twice daily; maximum 1000 mg/day. For other indications: 5-10 mg/kg/dose every 8-12 hours.
For inflammatory conditions: 1-2 mg/kg/day in 3-4 divided doses; maximum 4 mg/kg/day or 200 mg/day. For patent ductus arteriosus: IV 0.2-0.25 mg/kg/dose every 12-24 hours for 3 doses.
Start at lowest effective dose (250 mg twice daily); monitor renal function and gastrointestinal bleeding risk.
Initiate at 25 mg twice daily; maximum 100 mg/day; monitor renal function and GI bleeding risk.
Cardiovascular Risk: NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk increases with duration of use and in patients with cardiovascular disease or risk factors. Indomethacin is contraindicated for treatment of perioperative pain in coronary artery bypass graft (CABG) surgery. Gastrointestinal Risk: NSAIDs increase the risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time without warning symptoms, and elderly patients and those with prior history of peptic ulcer disease or GI bleeding are at greater risk.
Cardiovascular thrombotic events; GI bleeding, ulceration, and perforation; renal toxicity including renal papillary necrosis; anemia; hepatic effects; hypertension; exacerbation of asthma; fluid retention; skin reactions including Stevens-Johnson syndrome; central nervous system effects including dizziness and headache; use in pregnancy (avoid in third trimester).
History of allergic reaction to indomethacin or aspirin; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; active GI bleeding or peptic ulcer disease.
Naproxen may be taken with food or milk to minimize gastrointestinal irritation. Avoid alcohol, as it increases the risk of stomach bleeding. No specific food restrictions beyond general NSAID precautions.
Avoid alcohol, as it increases the risk of gastrointestinal bleeding and liver toxicity. Take with food or milk to minimize gastrointestinal irritation. Limit salt intake to reduce fluid retention and hypertension risk. Avoid high-potassium foods if renal impairment is present, as indomethacin can increase potassium levels.
Naproxen is excreted into breast milk in small amounts (M/P ratio approximately 0.01). The relative infant dose is about 1% of the maternal weight-adjusted dose. Use with caution in breastfeeding; monitor infant for gastrointestinal effects, rash, or bleeding.
Indomethacin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.4). Use with caution, especially in infants with known cardiovascular or renal compromise. Consider alternatives if possible.
Due to increased renal clearance and volume of distribution in pregnancy, standard doses may be subtherapeutic; however, increased doses are not recommended due to fetal risks. Use lowest effective dose for shortest duration; avoid in third trimester.
Due to increased volume of distribution and clearance, dose adjustments are not routinely recommended. However, use lowest effective dose for shortest duration; avoid use after 30 weeks gestation.
Take with food or milk to reduce stomach upset.,Do not take more than the recommended dose; overdose can cause serious side effects.,Avoid alcohol while taking this medication to lower the risk of stomach bleeding.,Tell your doctor if you have a history of stomach ulcers, high blood pressure, or kidney disease.,Watch for signs of stomach bleeding: black/tarry stools, vomit that looks like coffee grounds.,Stop taking and seek medical help if you experience chest pain, weakness, slurred speech, or shortness of breath.,Store at room temperature away from moisture and heat.,Do not combine with other products containing naproxen or other NSAIDs.
Take with food, milk, or an antacid to reduce stomach upset.,Report any black/bloody stools, coffee-ground vomit, chest pain, shortness of breath, or signs of bleeding immediately.,Avoid alcohol, aspirin, and other NSAIDs (e.g., ibuprofen, naproxen) while taking this medication.,Do not take if you are allergic to aspirin or any NSAID, or if you have a history of asthma attacks after taking these drugs.,Notify your healthcare provider if you have kidney disease, high blood pressure, heart disease, or are pregnant or breastfeeding.